Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “cyclophosphamide” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 29
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 29 pipeline programs matching "cyclophosphamide" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

29 results for “cyclophosphamide” Back to intelligence hub

Search results

Page 1 of 2
  1. APHP200026

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial
  2. CYCLOPHOSPHAMIDE

    Pari Pharma GmbH

    The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT

    phase 3 small molecule active

    1 trial
  3. Cyclophosphamide

    Children's Hospital of Fudan University

    Stage III Kidney Wilms Tumor

    phase 3 small molecule active

    1 trial
  4. cyclophosphamide

    Partner Therapeutics Limited

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  5. BDH-CLL-002-2022/02/14

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial
  6. CYCLOPHOSPHAMIDE for Inoperable locally advanced or…

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial
  7. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial
  8. Cyclophosphamide

    Takeda

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

    phase 2 small molecule active

    1 trial
  9. Cyclophosphamide

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  10. Cyclophosphamide

    BEONE MEDICINES AUS PTY LTD

    Recurrent Transformed Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial
  11. Cyclophosphamide

    United Therapeutics Europe Ltd

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial
  12. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial
  13. Cyclophosphamide

    Karyopharm Therapeutics Inc

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial
  14. Cyclophosphamide

    ADC Therapeutics SA

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial
  15. Cyclophosphamide

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Pediatric

    phase 2 small molecule active

    1 trial
  16. Cyclophosphamide Doxorubicin Vincristine Lamivudine

    Taiwan Liposome Company

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial
  17. Cyclophosphamide+Pemetrexed+5-Fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Thyroid Gland Carcinoma

    phase 2 small molecule active

    1 trial
  18. cyclophosphamide

    Ultragenyx UK Limited

    Pemphigus

    phase 2 small molecule completed

    1 trial
  19. cyclophosphamide

    Ultragenyx UK Limited

    Anemia, Hemolytic, Autoimmune

    phase 2 small molecule completed

    1 trial
  20. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial
  21. BCA-81472709

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial
  22. Cyclophosphamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 small molecule active

    1 trial
  23. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Locally Advanced Melanoma

    phase 1 small molecule active

    1 trial
  24. Cyclophosphamide

    Nektar Therapeutics UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.